Notizie AIOM – anno XVI n. 657

9 Gennaio 2018

Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure The UPWARD Study

The androgen receptor inhibitor enzalutamide prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC). In controlled clinical studies, 0.5% (10 of 2051) of patients experienced seizure, but patients with a history of or risk factors for seizure ...
Leggi tutto

9 Gennaio 2018

OV21/PETROC: A randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer

The purpose of this multistage, adaptively, designed randomized phase II study was to evaluate the role of intraperitoneal (IP) chemotherapy following neoadjuvant chemotherapy (NACT) and optimal debulking surgery in women with epithelialovarian cancer (EOC). We performed ...
Leggi tutto

9 Gennaio 2018

Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial

Cabozantinib, an inhibitor of tyrosine kinases including MET, vascular endothelial growth factor receptors, and AXL, increased progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) in patients with advanced renal cell carcinoma (RCC) after ...
Leggi tutto

8 Gennaio 2018

Japan Approves Pembrolizumab for Urothelial Carcinoma

January 2, 2018 - The Japanese Ministry of Health, Labor and Welfare has approved the use of pembrolizumab for the treatment of patients with radically unresectable urothelial carcinoma who progressed after cancer chemotherapy, according to Merck, the manufacturer of the ...
Leggi tutto

8 Gennaio 2018

Howard A. ‘Skip’ Burris III, MD, FACP, FASCO, Elected ASCO President for 2019–2020 Term

December 19, 2017 - Howard A. “Skip” Burris III, MD, FACP, FASCO, a long-time member and volunteer, has been elected to serve as the President of ASCO for the term beginning in June 2019. He will take office as President-Elect during the ASCO Annual Meeting in ...
Leggi tutto

8 Gennaio 2018

Sexual Problems and Cancer: ASCO Clinical Practice Guideline Adaptation of CCO Guideline

December 21, 2017 - As reported in the Journal of Clinical Oncology by Jeanne Carter, PhD, of Memorial Sloan Kettering Cancer Center, and colleagues, ASCO has issued a clinical practice guideline adaptation of the Cancer Care Ontario (CCO) guideline on interventions to address ...
Leggi tutto

8 Gennaio 2018

FDA Grants Frontline Osimertinib Priority Review for NSCLC

December 18, 2017 - The FDA has granted a priority review to a supplemental new drug application (sNDA) for the use of osimertinib as a first-line treatment for patients with non–small cell lung cancer (NSCLC) whose tumors harbor EGFR mutations (exon 19 deletions or ...
Leggi tutto

8 Gennaio 2018

FDA proposes new, risk-based enforcement priorities to protect consumers from potentially harmful, unproven homeopathic drugs

December 18, 2017 - Today, the U.S. Food and Drug Administration proposed a new, risk-based enforcement approach to drug products labeled as homeopathic. To protect consumers who choose to use homeopathic products, this proposed new approach would update the FDA’s ...
Leggi tutto

8 Gennaio 2018

FDA Approves Adjuvant Pertuzumab Regimen for HER2+ Breast Cancer

December 20, 2017 - The FDA has approved pertuzumab in combination with trastuzumab and chemotherapy as an adjuvant treatment for patients with HER2-positive early breast cancer at high risk for recurrence, based on findings from the APHINITY trial. In the phase III trial, ...
Leggi tutto

8 Gennaio 2018

FDA Grants Apalutamide Priority Review for Nonmetastatic CRPC

December 21, 2017 - The FDA has granted a priority review to a new drug application (NDA) for apalutamide (ARN-509) for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC), according to Janssen Biotech, the manufacturer of the next-generation ...
Leggi tutto

LAVORIAMO CON

News

MEDICINA DI LABORATORIO, OLTRE IL 70% DELLE DECISIONI CLINICHE DIPENDE DALLE ANALISI. PRESENTATO IL PRIMO STUDIO NAZIONALE SULL’APPLICAZIONE DEL NUOVO NOMENCLATORE TARIFFARIO

TUMORI: “CNAO È CENTRO DI RIFERIMENTO MONDIALE NELL’ADROTERAPIA. A OGGI TRATTATI PIÙ DI 6.200 PAZIENTI”

MALATTIE AUTOIMMUNI: AL GIFFONI FILM FESTIVAL ARRIVA “PIÙ FORTE IO”. CON TENACIA E NUOVE TERAPIE POSSIBILE SUPERARE LE PATOLOGIE CRONICHE

L’OCULISTA: ANCHE IN ESTATE POSSIBILE FARSI OPERARE DI GLAUCOMA. PER PROTEGGERE GLI OCCHI BASTANO MASCHERINE, CAPPELLINI E OCCHIALI

MEDICINA DI LABORATORIO, I CLINICI ITALIANI RICONOSCIUTI TRA LE ECCELLENZE INTERNAZIONALI. “IL NOSTRO PAESE TRA I PROTAGONISTI DELL’EVOLUZIONE DELLA DIAGNOSTICA NEL MONDO”

TUMORE DELL’OVAIO, 1 DONNA SU 3 ASPETTA PIÙ DI UN ANNO PER LA DIAGNOSI. “NECESSARIO AUMENTARE L’ACCESSO AI CENTRI AD ALTO VOLUME, AL SUPPORTO PSICONCOLOGICO E ALL’INNOVAZIONE TERAPEUTICA”

TUMORE DEL SENO, IN ITALIA 950MILA DONNE VIVONO CON UNA DIAGNOSI. ROPI: ‘RACCOMANDATI ALMENO 150 MINUTI D’ATTIVITA’ FISICA ALLA SETTIMANA’

Notizie AIOM – anno XVI n. 657

Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure The UPWARD Study

OV21/PETROC: A randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer

Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial

Japan Approves Pembrolizumab for Urothelial Carcinoma

Howard A. ‘Skip’ Burris III, MD, FACP, FASCO, Elected ASCO President for 2019–2020 Term

Sexual Problems and Cancer: ASCO Clinical Practice Guideline Adaptation of CCO Guideline

FDA Grants Frontline Osimertinib Priority Review for NSCLC

FDA proposes new, risk-based enforcement priorities to protect consumers from potentially harmful, unproven homeopathic drugs

FDA Approves Adjuvant Pertuzumab Regimen for HER2+ Breast Cancer

FDA Grants Apalutamide Priority Review for Nonmetastatic CRPC